· Published by Health Canada · Official notice
This is duplicated text of a letter from Hoffmann-La Roche Limited. Contact the company for a copy of any references, attachments or enclosures.
Notice about Health Canada advisories
May 8, 2013
Dear Pharmacist/Chief of Medical Staff:
Please distribute to relevant Departments (that may be involved in the reconstitution and administration of CATHFLO, including Pharmacy, Intensive Care Unit, Oncology, Nephrology, Surgery, Internal Medicine, Anaesthesiology, Emergency Medicine, Cardiology), and other involved professional staff and post this NOTICE in your institution.
Subject: Particulate Matter Observed in Some Vials of CATHFLO® (alteplase): Additional Instructions for Use
Hoffmann-La Roche Limited (Roche), in consultation with Health Canada, would like to inform you that visible rubber stopper particulates have been observed in some vials of CATHFLO (alteplase) after reconstitution.
CATHFLO is a serine protease indicated for the restoration of function to central venous access devices.
Due to the medical necessity and to have continued availability of CATHFLO Roche is advising to:
Further Information
Hoffmann-La Roche has observed visible rubber stopper particulates in some vials of CATHFLO® (alteplase) following reconstitution. These particulates were observed in some vials but not all, and when present in a vial the number of particulates is low. An investigation into the source of the particulates is ongoing to determine the extent of the problem.
In the event you discover particulate matter upon reconstitution, do not administer CATHFLO to the patient. These visible particulates may pose a safety risk if administered to patients. Hoffmann-La Roche assesses the risk to patients as low when CATHFLO is administered for restoration of function to central venous access devices according to the "Preparation and Administration" section in the Product Monograph and package insert, which instructs health care providers to "inspect the product prior to administration for foreign matter and discolouration." When used according to the Product Monograph it is likely CATHFLO has minimal systemic exposure to the patient because the solution is withdrawn from the catheter after administration.
Based on a recent review of the company's adverse event surveillance systems, there have been no reports of adverse events that could be definitively attributed to the presence of particulate material in CATHFLO vials. However, to further minimize risk to patients, a filter needle should be used to withdraw the reconstituted product from the vial prior to patient administration.
Please ensure your staff and any provider in your institution who may be involved in the reconstitution and administration of CATHFLO receives a copy of this letter and specifically reviews the attached 'Instructions for Administration' for a complete guide to preparation and instillation of CATHFLO.
Managing marketed health product-related adverse reactions depends on health care professionals and consumers reporting them. Reporting rates determined on the basis of spontaneously reported post-marketing adverse reactions are generally presumed to underestimate the risks associated with health product treatments. Serious or unexpected adverse reactions in patients receiving CATHFLO should be reported to Roche or Health Canada.
Hoffmann-La Roche Limited
Drug Safety Department
2455 Meadowpine Boulevard
Mississauga, Ontario, L5N 6L7
or call toll free at: 1-888-762-4388
or fax at: 905-542-5864
or email to: mississauga.drug_safety@roche.com
To correct your mailing address or fax number, contact Hoffmann-La Roche Limited.
You can report any suspected adverse reactions associated with the use of health products to Health Canada by:
For other health product inquires related to this communication, please contact Health Canada at:
Biologics and Genetic Therapies Directorate (BGTD)
E-mail: BGTD_DGO_Enquiries@hc-sc.gc.ca
Tel: (613) 946-7264
Fax: (613) 946-5214
Should you have any questions or require additional information regarding the use of CATHFLO, please contact the Drug Information Department at Hoffmann-La Roche Limited at 1-888-762-4388, Monday to Friday, between 8:30 a.m. and 4:30 p.m. (Eastern Standard Time).
original signed by
Lorenzo Biondi,
Vice President, Medical and Regulatory Affairs
Hoffmann-La Roche Limited
(additions to current full Product Monograph Information in bold+italics)
Preparation of Solution
Reconstitute Cathflo® to a final concentration of 1 mg/mL:
No other medication should be added to solutions containing Cathflo®.
Administration
Any unused solution should be discarded.